Evidence map›Paper›PMID 40443907›Full record

ArticleF1000Research2025

Jose Vargas, Natalia Arbelaez, Denny Cardenas, Javier Murillo, Victoria Ospina, Sara Robledo, Javier Soto

Abstract read
In one paragraph

Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jose VargasBIOGEN-Universidad de Santander, Facultad de Ciencias Médicas y de la Salud, Instituto de Investigación Masira, Cúcuta, Colombia.
Natalia ArbelaezPECET-Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Denny CardenasBIOGEN-Universidad de Santander, Facultad de Ciencias Médicas y de la Salud, Instituto de Investigación Masira, Cúcuta, Colombia.
Javier MurilloGrupo Estudios Preclínicos, Corporación CIDEPRO, Medellín, Colombia.
Victoria OspinaGrupo Estudios Preclínicos, Corporación CIDEPRO, Medellín, Colombia.
Sara RobledoPECET-Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Javier SotoBIOGEN-Universidad de Santander, Facultad de Ciencias Médicas y de la Salud, Instituto de Investigación Masira, Cúcuta, Colombia.ORCID https://orcid.org/0000-0002-4786-3431

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric cancer is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Perioperative or adjuvant chemotherapy improves survival in patients with stage 1B or higher cancers. Methods: In order to evaluate this potential present in crude extracts of the leaves of these plants, as well as the seed oil of Results: All extracts tested were cytotoxic at 90 and 160 μg/ml concentrations Conclusion:

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicMoringa oleiferaPlant ExtractsStomach NeoplasmsApoptosisCell CycleCell Line, TumorCell ProliferationHumansPlant LeavesPlant OilsAntineoplastic AgentsAntineoplastic Agents, PhytogenicPlant ExtractsPlant Oilsantitumorapoptosiscytotoxicityleaf extractoil seedplants

Identifiers

PMID40443907
PMCPMC12120421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.